06/01/22 8:30 AMOTC : BNIGF covid-19low floatBeroni Group’s Enhanced COVID-19 Antigen Rapid Test Kit Received CE CertificationBeroni Group (OTCQX: BNIGF; NSX: BTG) (“Beroni”), an Australia-based biopharmaceutical enterprise, announced that it has received notification from its European Authorized Representative, CMC Medical Devices & Drugs SL, that its latestRHEA-AIvery positive
03/31/22 8:25 AMOTC : BNIGF managementlow floatBeroni Group Announces Appointment of Dr. John Chiplin to Board of DirectorsBeroni Group (OTCQX: BNIGF; NSX: BTG) (“Beroni” or the “Company”), an Australia-based diversified biopharmaceutical enterprise focused on the research, development, innovation and commercialization of therapies and products forRHEA-AIvery positive
03/23/22 2:00 PMOTC : BNIGF conferenceslow floatBeroni Group to Participate in the 2022 Virtual Growth Conference Presented by Maxim Group LLC and hosted by M-Vest on March 28th – 30th from 9:00 a.m. - 5:00 p.m. EDTBeroni Group (OTCQX: BNIGF; NSX: BTG) (“Beroni” or the “Company”), an Australia-based diversified biopharmaceutical enterprise focused on the research, development, innovation and commercialization of therapies and products forRHEA-AIneutral
01/31/22 8:30 AMOTC : BNIGF low floatBeroni Group Sets Up a New R&D Centre in High-Tech Hub in Zhuhai, ChinaBeroni Group (OTCQX: BNIGF; NSX: BTG) (“Beroni” or the “Company”), an Australia-based diversified biopharmaceutical enterprise focused on the research, development, innovation and commercialization of therapies and products forRHEA-AIneutral
11/18/21 8:30 AMOTC : BNIGF covid-19low floatBeroni Group Received a US$1.07 Million Order for COVID-19 Antigen Test Kits from JapanBeroni Group (OTCQX: BNIGF; NSX: BTG) (“Beroni” or the “Company”), an Australia-based diversified biopharmaceutical enterprise focused on the research, development, innovation and commercialization of therapies and products forRHEA-AIneutral
10/28/21 8:30 AMOTC : BNIGF low floatBeroni Group Published an Article Related to Single-Domain Antibodies in the FEBS JournalBeroni Group (OTCQX: BNIGF; NSX: BTG) (“Beroni” or the “Company”), an Australia-based biopharmaceutical enterprise, today announced that its article entitled “Crystal structures of the SARS-CoV-2 nucleocapsid protein C-terminalRHEA-AIneutral
09/09/21 8:30 AMOTC : BNIGF low floatBeroni Group Received Approval for 43.5% R&D Rebate from Australian Government for the Novel, Potential Anti-Cancer Drug PENAOBeroni Group (OTCQX: BNIGF; NSX: BTG) (“Beroni”), an Australia-based biopharmaceutical enterprise, today announced that PENAO Pty Ltd, its majority-owned, Sydney-based anti-cancer drug development company, has been approved by theRHEA-AIneutral
08/31/21 8:30 AMOTC : BNIGF clinical triallow floatBeroni Group Announced the Latest Clinical Study of its SARS-CoV-2 Antigen Test Kit (Colloidal Gold Method)Beroni Group (OTCQX: BNIGF; NSX: BTG) (“Beroni”), an Australia-based biopharmaceutical enterprise, announced the latest clinical study of its SARS-CoV-2 Antigen Test Kit (Colloidal Gold Method) demonstrated an overall sensitivityRHEA-AIneutral
08/18/21 8:30 AMOTC : BNIGF low floatBeroni Initiates Manufacture of its Novel, Potential Anti-Cancer Drug PENAOBeroni Group (OTCQX: BNIGF; NSX: BTG) (“Beroni”), an Australia-based diversified biopharmaceutical enterprise, announced that PENAO Pty Ltd, its majority-owned, Sydney-based anti-cancer drug development company, has signed a drugRHEA-AIneutral
05/28/21 8:30 AMOTC : BNIGF low floatBeroni Group Signs MoU with tella, Inc to Collaborate in Immunotherapy for Cancer TreatmentBeroni Group (OTCQX: BNIGF; NSX: BTG) (“Beroni” or the “Company”), an Australia-based diversified biopharmaceutical enterprise today announced that it has signed a Memorandum of Understanding with tella, Inc. (“tella”) toRHEA-AIpositive